Stockscreener 앱 받기
4.67
0.65%
0.03
전일 마감가:
$4.64
열려 있는:
$4.65
하루 거래량:
21.20M
Relative Volume:
0.59
시가총액:
$2.43B
수익:
$64.60M
순이익/손실:
$-377.75M
주가수익비율:
-3.0129
EPS:
-1.55
순현금흐름:
$-335.64M
1주 성능:
+0.21%
1개월 성능:
+11.19%
6개월 성능:
-13.36%
1년 성능:
-27.03%
1일 변동 폭
$4.55
$4.88
1주일 범위
$4.55
$4.98
52주 변동 폭
$3.79
$12.36
리커젼 파마 Stock (RXRX) Company Profile
명칭
Recursion Pharmaceuticals Inc
전화
(385) 269-0203
주소
41S RIO GRANDE STREET, SALT LAKE CITY
RXRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.67 | 2.41B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
리커젼 파마 Stock (RXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-07-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-22 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 개시 | Needham | Buy |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-04 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 개시 | Berenberg | Buy |
| 2021-05-11 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Goldman | Neutral |
| 2021-05-11 | 개시 | JP Morgan | Neutral |
| 2021-05-11 | 개시 | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 개시 | SVB Leerink | Outperform |
모두보기
리커젼 파마 주식(RXRX)의 최신 뉴스
Is Meta Stock a Buy Going Into 2026? - AOL.com
Is It Time To Reassess Recursion Pharmaceuticals (RXRX) After Recent Share Price Weakness - simplywall.st
Is Recursion Pharmaceuticals (RXRX) Pricing In Its AI Drug Discovery Ambitions? - Yahoo Finance
2 AI stocks to buy in 2026, and 1 to avoid - MSN
2 AI Stocks to Buy in 2026, and 1 to Avoid - Finviz
Recursion Pharmaceuticals: Stock Unresponsive To Clinical Updates (NASDAQ:RXRX) - Seeking Alpha
Assessing Recursion Pharmaceuticals (RXRX) Valuation After JP Morgan Update And REC-4881 Clinical Milestones - simplywall.st
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
How Recursion’s AI Drug Platform Progress And Extended Runway At Recursion Pharmaceuticals (RXRX) Has Changed Its Investment Story - simplywall.st
Recursion Pharmaceuticals patents PIKfyve inhibitors - BioWorld MedTech
How does Recursion Pharmaceuticals Inc score in quality rankingsStop Loss & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Potential Upside Amidst Biotechnology Challenges - DirectorsTalk Interviews
Market Outlook: Is Recursion Pharmaceuticals Inc stock overvalued by current metrics2025 Retail Activity & Safe Entry Momentum Tips - Bộ Nội Vụ
Why Recursion Pharmaceuticals (RXRX) stock is up today: a new JPM deck put cash runway back in focus - TechStock²
Why Recursion Pharmaceuticals Stock Is Quietly Climbing - TipRanks
Recursion Updates AI Drug Platform, Financial Outlook at JPM - TipRanks
Recursion Pharmaceuticals, Inc. Releases Updated Investor Presentation - TradingView — Track All Markets
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Will Recursion Pharmaceuticals Inc. stock benefit from infrastructure spendingStock Surge & Detailed Earnings Play Alerts - ulpravda.ru
Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know - sharewise.com
Insider Sell: Blake Borgeson Sells 220,000 Shares of Recursion P - GuruFocus
Recursion Pharmaceuticals (NASDAQ:RXRX) Director Blake Borgeson Sells 220,000 Shares - MarketBeat
Recursion Pharmaceuticals Insider Sold Shares Worth $959,200, According to a Recent SEC Filing - MarketScreener
Can Recursion Pharmaceuticals Inc. stock surprise with earnings upsideJuly 2025 Macro Moves & Free Community Consensus Stock Picks - ulpravda.ru
Aug Setups: How Recursion Pharmaceuticals Inc. stock performs after earningsJuly 2025 Opening Moves & Safe Entry Momentum Tips - ulpravda.ru
Recursion pharma director Gibson sells $170k in shares By Investing.com - Investing.com Nigeria
Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates - Finviz
Recursion’s Stock Surge: An Opportunity? - StocksToTrade
Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week’s Business Updates - Insider Monkey
Recursion Pharmaceuticals Stock Surges: What’s Happening? - timothysykes.com
RXRX Stock’s Impressive Surge: A Closer Look - timothysykes.com
Why Recursion Pharmaceuticals (RXRX) Is Up 10.7% After Positive REC-4881 Trial Data And Rising Analyst Focus - simplywall.st
Recursion Pharmaceuticals Inc Stock Analysis and ForecastLow Risk Investment Ideas & AI-Based Insights for Consistent Profits - earlytimes.in
Recursion Pharmaceuticals, Inc. (RXRX) Investor Outlook: Uncovering a 60% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. - AOL.com
Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Is Recursion Pharmaceuticals (RXRX) Mispriced After Volatile Share Performance And Ongoing Tech Partnerships - simplywall.st
Here’s what JP Morgan thinks about Recursion Pharmaceuticals (RXRX) - MSN
JPMorgan boosts rating on Recursion Pharmaceuticals (RXRX) amid AI-driven drug pipeline - MSN
Should J.P. Morgan’s REC-4881 Upgrade and TUPELO Data Require Action From Recursion (RXRX) Investors? - Yahoo Finance
Recursion Pharmaceuticals (RXRX): Assessing Valuation After New Activist Investor Filings With the SEC - simplywall.st
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2024 Earnings Call Transcript - MSN
Recursion Pharmaceuticals Stock (RXRX) Opinions on Analyst Upgrade and Insider Trading - Quiver Quantitative
Here’s What J.P. Morgan Thinks About Recursion Pharmaceuticals (RXRX) - Insider Monkey
JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline - Finviz
Bank Pictet & Cie Europe AG Acquires Shares of 1,630,000 Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals reports positive Phase 1b/2 TUPELO trial results, validating AI-driven therapy for FAP - MSN
Cathie Wood’s ARK Investment buys 755K shares of Recursion Pharmaceuticals, Inc. (RXRX) - MSN
Cathie Wood’s ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX) - Yahoo Finance
리커젼 파마 (RXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
리커젼 파마 주식 (RXRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Gibson Christopher | Director |
Jan 05 '26 |
Sale |
4.25 |
40,000 |
170,000 |
933,839 |
4.73%
0.92%
자본화:
|
볼륨(24시간):